Search Results - "Ismael, Gustavo"

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial by Ismael, Gustavo, Dr, Hegg, Roberto, MD, Muehlbauer, Susanne, PhD, Heinzmann, Dominik, PhD, Lum, Bert, PharmD, Kim, Sung-Bae, MD, Pienkowski, Tadeusz, MD, Lichinitser, Mikhail, MD, Semiglazov, Vladimir, MD, Melichar, Bohuslav, MD, Jackisch, Christian, Prof

“…Summary Background A subcutaneous formulation of trastuzumab has been developed, offering potential improvements in patient convenience and resource use…”
Get full text

Novel cytotoxic drugs: Old challenges, new solutions by Ismael, Gustavo F.V, Rosa, Daniela Dornelles, Mano, Max S, Awada, Ahmad

“…Summary The discovery of cytotoxic agents was revolutionary for anticancer therapy in the last century, improving survival rates and the quality of life of…”
Get full text

The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours by Mano, Max S, Rosa, Daniela D, De Azambuja, Evandro, Ismael, Gustavo F.V, Durbecq, Virginie

“…Summary Her2 and topoisomerase-IIα (T2A) gene amplification are separate events, although the latter is more frequently seen in Her2 amplified (34–90%) than in…”
Get full text

OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy by Rosa, Daniela D, Ismael, Gustavo F V, de Azambuja, Evandro, Braga, Sofia, Cardoso, Fatima, Bleiberg, Harry

Get full text

Trastuzumab (Herceptin) for Early-Stage Breast Cancer by Ismael, Gustavo, MD, Rosa, Daniela Dornelles, MD, PhD, de Azambuja, Evandro, MD, Braga, Sofia, MD, Piccart-Gebhart, Martine, MD, PhD

“…Breast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free…”
Get full text

Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer by van Mackelenbergh, Marion T, Loibl, Sibylle, Untch, Michael, Buyse, Marc, Geyer, Jr, Charles E, Gianni, Luca, Schneeweiss, Andreas, Conte, Pierfranco, Piccart, Martine, Bonnefoi, Herve, Jackisch, Christian, Nekljudova, Valentina, Tang, Gong, Valagussa, Pinuccia, Neate, Colin, Gelber, Richard, Poncet, Coralie, Squifflet, Pierre, Saad, Everardo D, Heinzmann, Dominik, Denkert, Carsten, Rastogi, Priya, Cortes, Javier, Guarneri, Valentina, de Azambuja, Evandro, Cameron, David, Ismael, Gustavo, Wolmark, Norman, Cortazar, Patricia

“…The achievement of pathologic complete response (pCR) is strongly prognostic for event-free survival (EFS) and overall survival (OS) in patients with early…”
Get full text

Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy by Squifflet, Pierre, Saad, Everardo D, Loibl, Sibylle, van Mackelenbergh, Marion T, Untch, Michael, Rastogi, Priya, Gianni, Luca, Schneeweiss, Andreas, Conte, Pierfranco, Piccart, Martine, Bonnefoi, Hervé, Jackisch, Christian, Nekljudova, Valentina, Tang, Gong, Valagussa, Pinuccia, Neate, Colin, Gelber, Richard, Poncet, Coralie, Heinzmann, Dominik, Denkert, Carsten, Geyer, Jr, Charles E, Cortes, Javier, Guarneri, Valentina, de Azambuja, Evandro, Cameron, David, Ismael, Gustavo, Wolmark, Norman, Cortazar, Patricia, Buyse, Marc

“…Pathologic complete response (pCR) has prognostic importance and is frequently used as a primary end point, but doubts remain about its validity as a surrogate…”
Get full text

Abstract P5-06-02: Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC) by Loibl, Sibylle, Untch, Michael, Buyse, Marc, Robidoux, André, Gianni, Luca, Schneeweiss, Andreas, Conte, Pierfranco, Piccart, Martine, Bonnefoi, Hervé, Jackisch, Christian, Nekljudova, Valentina, Costantino, Joseph, Valagussa, Pinuccia, Neate, Colin, Gelber, Richard, Poncet, Coralie, Squifflet, Pierre, Saad, Everardo, Heinzmann, Dominik, Denkert, Carsten, Geyer, Charles E, Cortes, Javier, Guarneri, Valentina, de Azambuja, Evandro, Cameron, David, Ismael, Gustavo, von Minckwitz, Gunter, Wolmark, Norman, Cortazar, Patricia

“…Background: The achievement of pCR (breast and axilla) is strongly prognostic for event-free (EFS) and overall survival (OS) in EBC (Cortazar 2014), and…”
Get full text

Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission by Smaletz, Oren, Ismael, Gustavo, Del Pilar Estevez-Diz, Maria, Nascimento, Ivana L O, de Morais, Ana Luiza Gomes, Cunha-Junior, Geraldo Felício, Azevedo, Sergio J, Alves, Venancio A, Moro, Ana Maria, Yeda, Fernanda P, Dos Santos, Mariana Lopes, Majumder, Indrani, Hoffman, Eric W

“…To investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with…”
Get more information

Molecular-targeted therapies: Lessons from years of clinical development by Rosa, Daniela D, Ismael, Gustavo, Lago, Lissandra Dal, Awada, Ahmad

“…Summary Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-endocrine drugs in the treatment of cancer, with the aim to…”
Get full text

Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR) by Smaletz, Oren, Ismael, Gustavo, Estevez-Diz, Maria Del Pilar, Nascimento, Ivana Lucia Oliveira, Wiermann, Ana Luiza Gomes de Morais, Cunha, Geraldo Felicio, Azevedo, Sergio J, Alves, Venâncio A, Moro, Ana M, Yeda, Fernanda Perez, dos Santos, Mariana Lopes, Majumder, Indrani, Hoffman, Eric W.

“…Abstract only e17039 Background: Lewis-Y (LeY) antigen is a blood group related antigen expressed in 75% of OC. hu3S193 is a humanized anti-LeY IgG1 mAb with…”
Get full text

The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck by Awada, Ahmad, Ismael, Gustavo

“…There have been important advances in the treatment of locally advanced squamous cell carcinoma of the head and neck (SCCHN). For patients with unresectable…”
Get full text

Molecular Profiling of a Tumor of Unknown Origin by Ismael, Gustavo, de Azambuja, Evandro, Awada, Ahmad

“…To the Editor: A 26-year-old woman had had abdominal pain since the beginning of her pregnancy. Endoscopy of the esophagus, stomach, and duodenum and abdominal…”
Get full text

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study) by Gómez, Henry L, Neciosup, Silvia, Tosello, Célia, Mano, Max, Bines, José, Ismael, Gustavo, Santi, Patrícia X, Pinczowski, Hélio, Nerón, Yeni, Fanelli, Marcello, Fein, Luis, Sampaio, Carlos, Lerzo, Guillermo, Capó, Adolfo, Zarba, Juan J, Blajman, César, Varela, Mirta S, Martínez-Mesa, Jeovany, Werutsky, Gustavo, Barrios, Carlos H

“…Micro-Abstract In LACOG 0801 phase II study 142 patients with HER2+ MBC with progression after taxane were randomized between Lapatinib (L) combined with…”
Get full text

A randomized, open-label, phase II study of lapatinib / capecitabine, lapatinib / vinorelbine, or lapatinib / gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801 / EGF111792) by Gomez, Henry Leonidas, Neciosup, Silvia P., Tosello, Celia, Xavier, Patricia, Neron do Nascimento, Yeni, Fanelli, Marcelo, Ismael, Gustavo, Bines, Jose, Sampaio, Carlos, Lerzo, Guillermo Luis, Capo, Adolfo Miguel, Mano, Max S., Fein, Luis, Werutsky, Gustavo, Barrios, Carlos H.

“…Abstract only e11087 Background: Lapatinib-capecitabine is approved for the treatment of ErbB2-amplified metastatic breast cancer (MBC) after failure to…”
Get full text

Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP) by Ades, Felipe, Azambuja, Evandro de, Daugaard, Gedske, Ameye, Lieveke, Moulin, Camilo, Paesmans, Marianne, Jong, Daphne De, Decoster, Lore, Greve, Jacques De, Ismael, Gustavo, Møller, Anne Kirstine, Piccart, Martine, Awada, Ahmad

“…CupPrint® is a genomic signature able to identify 47 different cancer types. The aim of our study was to compare the accuracy of this genomic signature to that…”
Get full text

The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours by Mano, Max S, Rosa, Daniela D, De Azambuja, Evandro, Ismael, Gustavo F V, Durbecq, Virginie

“…Her2 and topoisomerase-IIalpha (T2A) gene amplification are separate events, although the latter is more frequently seen in Her2 amplified (34-90%) than in…”
Get full text

Molecular profiling of a tumor of unknown origin by Ismael, Gustavo, de Azambuja, Evandro, Awada, Ahmad

Get full text